- Home
- PVLA
PVLA
Palvella Therapeutics Inc. Common Stock
as 02-21-2025 4:00pm EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 15.9M | IPO Year: | N/A |
| Target Price: | $40.33 | AVG Volume (30 days): | 49.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.20 - $22.32 | Next Earning Date: | 03-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Palvella Therapeutics Inc. Common Stock News
PVLA Breaking Stock News: Dive into PVLA Ticker-Specific Updates for Smart Investing
TipRanks
a day ago
Palantir initiated, Roku upgraded: Wall Street’s top analyst calls
GlobeNewswire
12 days ago
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
GlobeNewswire
a month ago
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
GlobeNewswire
a month ago
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
TipRanks
2 months ago
Palvella Therapeutics initiated with a Buy at H.C. Wainwright
Compare PVLA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PVLA Palvella Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.